Drugs / mFOLFIRINOX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04835064 | Apr 2021 → Apr 2024 | pancreatic adenocarcinoma | Fudan University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT07522073 Background | Apr 2026 → Sep 2028 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Jeil Pharmaceutical Co., Ltd. | Results 온코닉테라퓨틱스 ‘네수파립’, ASCO2026서 전이성 췌장암 1차 치료제 가능성 입증 jeilpharm.co.kr ↗
네수파립은 또 다른 표준치료법인 mFOLFIRINOX 병용군에서도 ORR 38.5%, DCR 92.3%, mOS 18.5 개월을 기록하며 우수한 치료 효과를 보였다 . |
| 2026-04-22 | NETRIS Pharma | Results NETRIS Pharma : Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody netrispharma.com ↗
LAPC patients treated with NP137 and mFOLFIRINOX achieved a median progression free survival (PFS) of 10.85 months, median overall survival (OS) of 16.43 months and a 23% conversion-to-surgery rate |
| 2025-01-22 | Oncolytics Biotech | Results Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium oncolyticsbiotech.com ↗
Our new safety data indicate its ability to also be combined with modified FOLFIRINOX, thus expanding its potential to benefit patients with metastatic pancreatic cancer. |
| 2025-01-15 | Oncolytics Biotech | Regulatory Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data oncolyticsbiotech.com ↗
Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. |
| 2024-12-03 | Oncolytics Biotech | Results Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort oncolyticsbiotech.com ↗
Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab |
| 2024-05-09 | Oncolytics Biotech | Regulatory Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer oncolyticsbiotech.com ↗
Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC. |
| 2024-03-05 | Oncolytics Biotech | Regulatory Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN oncolyticsbiotech.com ↗
This amendment will be reviewed by the Paul Ehrlich Institute (PEI; Germany’s regulatory body) for approval before patient enrollment can begin. |
| 2022-09-14 | Alligator Bioscience AB | Results Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1 Phase 1b/2 Trial at AACR Special Conference on Pancreatic Cancer 2022 alligatorbioscience.se ↗
Data from Phase 1b dose escalation part of the study shows that mitazalimab combined with mFOLFIRINOX is safe and well tolerated |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mFOLFIRINOX | “mFOLFIRINOX” NCT07522073 ↗ |
| Known as | calcium leucofolate | “calcium leucofolate \[LV\]” NCT04835064 ↗ |
| Route | Intravenous | “LV 400 mg/m2 intravenous infusion for 2 h, Day 1” NCT04835064 ↗ |